Vir Biotechnology, Inc. (VIR)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Marianne De Backer M.B.A., M.Sc., Ph.D. | CEO & Director | 4.79M | -- | 1969 |
| Mr. Jason O'Byrne M.B.A. | Executive VP & CFO | 280.49k | -- | 1969 |
| Ms. Vanina de Verneuil J.D. | Executive VP, General Counsel & Corporate Secretary | 1.1M | -- | 1979 |
| Dr. Mark D. Eisner M.D., M.P.H. | Executive VP & Chief Medical Officer | 978.42k | -- | 1966 |
| Dr. Lawrence Corey M.D. | Co-Founder & Scientific Advisor | -- | -- | 1947 |
| Dr. Louis J. Picker M.D. | Co-Founder & Scientific Advisor | -- | -- | -- |
| Mr. Brent Sabatini | Senior VP, Principal Accounting Officer & Chief Accounting Officer | -- | -- | 1974 |
| Dr. Maninder Hora Ph.D. | Executive VP & Chief Technical Operations Officer | -- | -- | 1954 |
| Dr. Jennifer Eileen Towne Ph.D. | Executive VP & Chief Scientific Officer | -- | -- | -- |
| Mr. Toby Medaris | Senior Vice President of Human Resources | -- | -- | -- |
Vir Biotechnology, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 408
Description
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Corporate Governance
Upcoming Events
July 30, 2025 at 10:59 AM UTC - August 4, 2025 at 12:00 PM UTC
Vir Biotechnology, Inc. Earnings Date